The Stay Study: A Demonstration Project Advancing PrEP Delivery in the San Francisco Bay Area Transgender Community

PHASE4CompletedINTERVENTIONAL
Enrollment

158

Participants

Timeline

Start Date

August 8, 2017

Primary Completion Date

August 27, 2020

Study Completion Date

December 1, 2020

Conditions
Transgender PersonsPre-Exposure Prophylaxis
Interventions
DRUG

Emtricitabine / Tenofovir Disoproxil Oral Tablet

Open-label emtricitabine 200mg/tenofovir 300mg

BEHAVIORAL

PrEP support

HIV/STI testing and counseling, adherence counseling, medical exams, safety monitoring, short message system (SMS), ie text message, and peer support, panel management.

Trial Locations (5)

94102

Bridge HIV, San Francisco Department of Public Health, San Francisco

Tom Waddell Urban Health Clinic, San Francisco

94109

San Francisco Community Health Clinic, San Francisco

94114

Castro-Mission Health Center, San Francisco

94538

Tri-City Health Center, Fremont

All Listed Sponsors
collaborator

San Francisco Department of Public Health

OTHER_GOV

collaborator

University of California, San Francisco

OTHER

collaborator

San Francisco Community Health Center

UNKNOWN

collaborator

Tri-City Health Center

UNKNOWN

collaborator

California HIV/AIDS Research Program

OTHER

lead

Public Health Foundation Enterprises, Inc.

OTHER

NCT03120936 - The Stay Study: A Demonstration Project Advancing PrEP Delivery in the San Francisco Bay Area Transgender Community | Biotech Hunter | Biotech Hunter